Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma
Authors
Diab, ATykodi, S
Curti, B
Cho, D
Wong, M
Puzanov, I
Lewis, K
Maio, M
Daniels, G
Spira, A
Tagliaferri, M
Hannah, A
Clemens, W
Imperiale, M
Bernatchez, C
Haymaker, C
Bentebibel, S
Zalevsky, J
Hoch, U
Fanton, C
Rizwan, A
Aung, S
Cattaruzza, F
Iaccucci, E
Sawka, D
Bilen, M
Lorigan, Paul C
Grignani, G
Larkin, J
Jang, S
Warzocha, E
Sznol, M
Hurwitz, M
Affiliation
Memorial Sloan Kettering Cancer Center, New YorkIssue Date
2019
Metadata
Show full item recordCitation
Diab A, Tykodi S, Curti B, Cho D, Wong M, Puzanov I, et al. Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018); Nov 6; Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018. p. 115.Journal
Journal for Immunotherapy of CancerDOI
10.1186/s40425-018-0423-xAdditional Links
https://dx.doi.org/10.1186/s40425-018-0423-xType
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1186/s40425-018-0423-x